View Older Stories View More Recent Stories

Oct 16, 2023 07:00PM FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as
Oct 16, 2023 06:45AM Merck (MRK) Announces EU Approval of KEYTRUDA as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
Oct 16, 2023 06:45AM European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chem
Oct 13, 2023 07:45AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-
Oct 13, 2023 07:45AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Ex
Oct 10, 2023 06:46AM Merck (MRK) Highlights Innovative Oncology Portfolio and Pipeline
Oct 10, 2023 06:45AM Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease
Oct 10, 2023 06:31AM Merck (MRK) Reports KEYNOTE-671 Trial Meets Dual Primary Endpoint
Oct 10, 2023 06:30AM Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
Oct 5, 2023 07:01AM Merck (MRK) KEYTRUDA Met Primary Endpoint of DFS in Certain Patients With MIUC After Surgery
Oct 5, 2023 07:00AM Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery
Oct 5, 2023 06:45AM Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26
Sep 28, 2023 06:46AM Merck (MRK) Granted FDA Priority Review for Sotatercept
Sep 28, 2023 06:45AM Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
Sep 26, 2023 04:00AM MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services
Sep 22, 2023 06:46AM Merck (MRK) and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Sep 22, 2023 06:45AM Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Sep 22, 2023 06:00AM Merck (MRK) Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival
Sep 22, 2023 06:00AM Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced
Sep 20, 2023 06:45AM Merck (MRK) Granted FDA Priority Review for KEYTRUDA Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Sep 20, 2023 06:45AM FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical
Sep 19, 2023 06:45AM Merck (MRK) Announces FDA Acceptance for Priority Review of NDA for WELIREG
Sep 19, 2023 06:45AM FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Sep 15, 2023 09:10AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based C
Sep 15, 2023 09:10AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Plat
Sep 11, 2023 07:45AM Merck (MRK) Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with PAH
Sep 11, 2023 07:45AM Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
Sep 7, 2023 06:46AM Merck (MRK) Announces Expanded EU Indication for ERVEBO to Include Children 1 Year of Age and Older
Sep 7, 2023 06:45AM European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
Sep 5, 2023 08:05AM Merck (MRK) Reports Publication of Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL9
Sep 5, 2023 08:00AM Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics
Sep 5, 2023 06:45AM Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Aug 29, 2023 06:50AM Merck (MRK) Announces EU Approval of KEYTRUDA Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing
Aug 29, 2023 06:50AM European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma E
Aug 29, 2023 06:45AM Merck to Participate in the Citi 18th Annual BioPharma Conference
Aug 25, 2023 06:31AM Merck (MRK) Initiates Phase 3 Clinical Program for MK-0616
Aug 25, 2023 06:30AM Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Aug 25, 2023 06:24AM Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-010 Trial of KEYTRUDA pus LENVIMA
Aug 25, 2023 06:15AM Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squam
Aug 24, 2023 06:45AM Merck (MRK) Reports LYNPARZA Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Aug 24, 2023 06:45AM LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Aug 18, 2023 06:46AM Merck (MRK) Reports WELIREG Phase 3 LITESPARK-005 Trial Met Primary Endpoint
Aug 18, 2023 06:45AM Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Aug 8, 2023 04:01PM Ligand Reports Second Quarter 2023 Financial Results
Aug 7, 2023 08:30AM Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
Aug 3, 2023 06:45AM Merck (MRK) Announces FDA Approval of ERVEBO for Use in Children 12 Months of Age and Older
Aug 3, 2023 06:45AM U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
Aug 1, 2023 06:30AM Merck Announces Second-Quarter 2023 Financial Results
Aug 1, 2023 05:57AM Busy earnings day, Meta reportedly prepares AI chatbot - what's moving markets
Jul 28, 2023 06:45AM Merck (MRK) Reports Phase 3 KEYNOTE-756 Trial Met Primary Endpoint
View More Recent Stories View Older Stories